Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study)

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

(2015) Adrian Wagg et al.   CUAJ-Canadian Urological Association Journal

Persistence with mirabegron therapy for overactive bladder: A real life experience

(2015) Nisha Pindoria et al.   NEUROUROLOGY AND URODYNAMICS

Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder

(2014) Osamu Yamaguchi et al.   BJU INTERNATIONAL

Is there seasonal variation in symptom severity, uroflowmetry and frequency–volume chart parameters in men with lower urinary tract symptoms?

(2014) Rufus Cartwright et al.   SCOTTISH MEDICAL JOURNAL

Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison

(2013) Khaled Maman et al.   EUROPEAN UROLOGY

Prevalence and factors associated with xerostomia and hyposalivation among community-dwelling older people in Japan

(2013) Yuki Ohara et al.   GERODONTOLOGY

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

(2012) Adrian Wagg et al.   BJU INTERNATIONAL

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

(2012) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline

(2012) E. Ann Gormley et al.   JOURNAL OF UROLOGY

Long-Term Safety and Efficacy of Two Different Antimuscarinics, Imidafenacin and Solifenacin, for Treatment of Overactive Bladder: A Prospective Randomized Controlled Study

(2012) Teruhiko Yokoyama et al.   UROLOGIA INTERNATIONALIS

Relationship between Toe Temperature and Lower Urinary Tract Symptoms

(2012) Hiroo INOUE et al.   LUTS-Lower Urinary Tract Symptoms

Selective Binding of Bladder Muscarinic Receptors in Relation to the Pharmacokinetics of a Novel Antimuscarinic Agent, Imidafenacin, to Treat Overactive Bladder

(2010) S. Yamada et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Patient-reported reasons for discontinuing overactive bladder medication

(2009) Joshua S. Benner et al.   BJU INTERNATIONAL

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder

(2009) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

(2008) Christopher R. Chapple et al.   EUROPEAN UROLOGY